Latest Intelligence on Pharmaceuticals and Healthcare in Denmark

Published within

« | 1 | 2 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Schering-Plough/Centocor: wider Remicade indication

Published By Datamonitor
06 Feb 2001
ResearchWire
ResearchWire

Parallel importing: weak Euro means strong growth

Published By Datamonitor
01 May 2001
CommentWire
CommentWire

Novo Nordisk: high risk but big prize without Novartis

Novo Nordisk has lost its partner in the development of NN6622, a new insulin sensitizer for the treatment of type 2 diabetes. The company's decision to continue the development of this compound alone carries a high risk. However, in the unlikely event that it does launch, the rewards for Novo Nordisk would be extremely high.

Published By Datamonitor
01 Nov 2001
CommentWire
CommentWire

Lundbeck/Merz: the first drug for severe Alzheimer's

Lundbeck, which has in-licensed the drug from Merz, aims to launch Ebixa this year. It is the first approved treatment for severe AD. The high patient potential in this segment of the AD market will likely bring the drug's manufacturers strong returns. However, market leadership may be short lived: the makers of current AD drugs expect approvals for severe AD by the end of 2003.

Published By Datamonitor
21 Feb 2002
Expert View
Expert View

Alzheimer's disease: an opportunity for expansion?

Alzheimer's disease is reaching epidemic proportions. However, less than half of those affected seek diagnosis, mistakenly believing that there are no effective treatments available. With the number of sufferers set to triple in the next 30-40 years, many drug companies are battling to grab a share of this lucrative market, but will they be able to develop drugs effective enough to capitalize?

Published By Datamonitor
03 May 2002
CommentWire
CommentWire

Novo Nordisk/Dr Reddy's: cancer fears freeze diabetes drug

Novo Nordisk has suspended human trials of ragaglitazar, after discovering tumors in rodents that had been fed the experimental drug. The possible loss of ragaglitazar, which had been forecast peak annual sales of $1.78 billion, is Novo Nordisk's third setback this year. It also hits the drug's originator Dr Reddy's hard.

Published By Datamonitor
23 Jul 2002
CommentWire
CommentWire

Cialis: standing ovation for new launch

The launch of Viagra, the world's first treatment for impotency and erectile dysfunction, was an instant success. Now, Lilly ICOS has officially launched Cialis, Viagra's first direct competition, and there is more on the way. In a growing market, Cialis' advantages over Viagra mean that it could reach blockbuster status.

Published By Datamonitor
05 Feb 2003
CommentWire
CommentWire

Ferring: strong R&D base for next generation incontinence treatment

Ferring's next generation of antidiuretics to treat urinary incontinence could make use of pioneering research by Nobel Laureate Professor Agre. The company's close relationship with academia and its own long history of research in the urinary incontinence field should strengthen its position as a leading urology player.

Published By Datamonitor
01 Mar 2004
CommentWire
CommentWire

Novo Nordisk/G2 Therapies: expanding operations

Novo Nordisk has signed a $100 million deal with Australian biotech firm G2 Therapies to develop a disease-modifying anti-rheumatic drug (DMARD). While the alliance should boost the fortunes of the relatively small biotech company and could aid Novo Nordisk in the potentially lucrative inflammation drugs market, a number of challenges lie ahead due to the nature of this market.

Published By Datamonitor
10 Feb 2006
Expert View
Expert View

Curalogic: closer to entering the immunotherapy arena

Curalogic has initiated a phase III trial with its product for oral immunotherapy of ragweed allergy. While traditional disease-modifying immunotherapeutics are administered by subcutaneous injection, Curalogic is developing a more convenient orally administered drug. Despite this advantage, a licensing-deal with a large respiratory player will be essential to exploit the drug's full potential.

Published By Datamonitor
14 Mar 2007

« | 1 | 2 | » »|

No help is available.